The diagnostic and prognostic role of liquid-based cytology: are we ready to monitor therapy and resistance?

References

• Fadda G, Rossi ED. Liquid based cytology in fine needle aspiration biopsies of the thyroid gland. Acta Cytol 2011;55:389-400
   PubMed Web of Science ®Google Scholar
• Schmitt FC, Longatto-Filho A, Valent A, Vielh P. Molecular techniques in cytopathology practice. J Clin Pathol 2008;61:258-67
   Google Scholar
• Cibas ED, Ali SZ. NCI Thyroid FNA State of the Science Conference: The Bethesda system for reporting thyroid cytopathology. Am J Clin Pathol 2009;132:658-65
   PubMed Web of Science ®Google Scholar
• Ren S, Solomides C, Draganova-Tacheva R, Bibbo M. Overview of nongunecological samples prepared with liquid based cytology medium. Acta Cytol 2014;58:522-32
   Google Scholar
• Simsir A, Rapkiewicz A, Cangiarella J. Current utilization of breast FNA in a cytology practice. Diagn Cytopathol 2008;19:271-8
   Google Scholar
• Rossi ED, Morassi F, Santeusanio G, et al. Thyroid fine-needle aspiration cytology processed by ThinPrep: an additional slide decreased the number of inadequate results. Cytopathol 2010;21:97-102
   Google Scholar
• Afify AM, Liu J, Al-Khafaji BM. Cytologic artefacts and pitfalls of thyroid fine needle aspiration using Thin Prep. Cancer Cytopathol 2001;93:179-86
   Google Scholar
• Rossi ED, Martini M, Capodimonti S, et al. Diagnostic and prognostic value of immunocytochemistry and BRAF mutation analysis on liquid based biopsies of thyroid neoplasms suspicious for carcinoma. Eur J Endocrin 2013;168:853-9
   PubMed Web of Science ®Google Scholar
• Rossi ED, Martini M, Capodimonti S, et al. BRAF (V600E) mutation analysis on LBC-processed aspiration biopsies predicts bilaterality and nodal involvement in papillary thyroid microcarcinoma. Cancer Cytopathol 2013;121:291-7
   Google Scholar
• Rossi ED, Martini M, Capodimonti S, et al. Analysis of immunocytochemistry and molecular BRAF expression in thyroid carcinoma: a Cyto-histological institutional experience. Cancer Cytopathol 2014. [Epub ahead of print]
   Google Scholar
• Cochand-Priollet B, Dahan H, Laloi-Michelin M, et al. Immunocytochemistry with cytokeratin-19 and HBME-1 increases the diagnostic accuracy of thyroid fine-needle aspirations. Preliminary report of 150 liquid – based fine needle aspirations with histological control. Thyroid 2011;21:1067-73
   PubMedGoogle Scholar
• Chang H, Lee H, Yoon SO, et al. BRAF (V600E) mutation analysis of liquid-based preparation-processed fine needle aspiration sample improves the diagnostic rate of papillary thyroid carcinoma. Human Pathol 2012;43:89-95
   Google Scholar
• Renshaw A. An estimate of risk of malignancy for a benign diagnosis in thyroid fine-needle aspirates. Cancer Cytopathol 2010;118:190-5
   Google Scholar
• Marchevsky AM, Walts AE, Bose S, et al. Evidence-based evaluation of the risks of malignancy predicted by thyroid fine-needle aspiration biopsies. Diagn Cytopathol 2010;38:252-9
   PubMedGoogle Scholar
• Baloch ZW, LiVolsi AV. Current role and value of fine-needle aspiration in nodular goiter. Best Pract Res Clin Endocrinol Metab 2014;28:531-44
   PubMed Web of Science ®Google Scholar
• Jung CK, Little MP, Lubin JH, et al. The increase in thyroid cancer incidence during the last four decades is accompanied by a high frequency of BRAF mutations and a sharp increase in RAS mutations. J Clin Endocrinol Metab 2013;10:2503-13
   Google Scholar
• Mathur A, Moses W, Rahbari R, et al. Higher rate of BRAF mutation in papillary thyroid cancer over time: A single institution study. Cancer 2011;117:4390-5
   Google Scholar
• Kim TH, Park YJ, Lim JA, et al. The association of the BRAFV600E mutation with prognostic factors and poor clinical outcome in papillary thyroid cancer. Cancer 2012;118:1764-73
   PubMed Web of Science ®Google Scholar
• Nikiforov YE. Molecular diagnostics of thyroid tumors. Arch Pathol Lab Med 2011;15:569-773
   Google Scholar
• Saleh HA, Hammoud J, Zakaria R, Khan AZ. Comparison of Thin-Prep and cell block preparation for the evaluation of Thyroid epithelial lesions on fine needle aspiration biopsy. Cytojournal 2008;25:5-3
   Google Scholar
• Correia-Rodrigues HG, Nogueira De Pontes AA, Adan LFF. Use of molecular markers in samples obtained from preoperative aspiration of thyroid. Endocr J 2012;59:417-24
   Google Scholar
• Fadda G, Rossi ED, Raffaelli M, et al. Follicular thyroid neoplasms can be classified as low and high risk according to HBME-1 and Galectin 3 expression on liquid based fine needle cytology. Eur J Endocrinol 2011;165:447-53
   Google Scholar
• Yeo MK, Liang ZL, Oh T, et al. Pyrosequencing cut-off value identifying BRAF V600E mutation in fine needle aspiration samples of thyroid nodules. Clin Endocrinol 2011;75:555-60
   Google Scholar
• Alexander EK, Kennedy GC, Baloch ZW, et al. Preoperative diagnosis of benign thyroid nodules with indeterminate cytology. N Engl J Med 2012;367:705-15
   PubMed Web of Science ®Google Scholar
• Diggans J, Kim SY, Hu Z, et al. Machine lerning fromconcept to clinic: reliable detection of BRAF V600E DNA mutations in thyroid nodules using high-dimensional RNA expression data. Pac Symp Biocomput 2015;20:371-82
   Google Scholar
• Ohori NP, Nikiforova MN, Schoedel KE, et al. Contribution of molecular testing to thyroid fine needle aspiration cytology of ‘Follicular lesion of undetermined significance/Atypia of undetermined significance’. Cancer Cytopathol 2010;118:17-23
   PubMed Web of Science ®Google Scholar
• Trovisco V, Vieira de Castro I, Soares P, et al. BRAF mutations are associated with some histological types of papillary thyroid carcinoma. J Pathol 2004;202:247-51
   PubMed Web of Science ®Google Scholar
• Yarchoan M, LiVolsi VA, Brose MS. RAF mutation and thyroid cancer recurrence. J Clin Oncol 2015;33:7-9
   Web of Science ®Google Scholar
• Xing M, Alzaharani AS, Carson KA, et al. Association between BRAF V600E mutation and recurrence of papillary thyroid cancer. J Clin Oncol 2015;33:42-50
   PubMed Web of Science ®Google Scholar
• Colanta A, Lin O, Tafe L, et al. BRAF mutation analysis of fine-needle aspiration biopsies of papillary thyroid carcinoma: impact on diagnosis and prognosis. Acta Cytolog 2011;55:563-9
   Google Scholar
• Barollo S, Pezzani R, Cristiani A, et al. Prevalence, tumorigenic role, and biochemical implications of rare BRAF alterations. Thyroid 2014;24:809-19
   Google Scholar
• Pennelli G, Vianello F, Barollo S. BRAF(K601E) mutation in a patient with a follicular thyroid carcinoma. Thyroid 2011;1:1393-139
   Google Scholar
• Zhang Y, Zhong Q, Chen X, et al. Diagnostic value of microRNAs in discriminating malignant thyroid nodules from benign ones on fine-needle aspiration samples. Tumor Biol 2014; doi 10.1007/S13277-014-2209-1
   Google Scholar
• Mazeh H, Mizrahi I, Halle D, et al. Development of a microRNA-based molecular assay for the detection of papillary thyroid carcinoma in aspiration biopsy samples. Thyroid 2011;21:111-18
   PubMed Web of Science ®Google Scholar
• Rothenberg SM, Mcfadden DG, Palmer EL, et al. Redifferentiation of iodine-refractory BRAF V600E-Mutant metastatic papillary thyroid cancer with dabrafenib. Clin Cancer Res 2015;21(5):1028-35
   PubMed Web of Science ®Google Scholar
• Siegel R, Naishadham D, Jemal A. Cancer statistics. Cancer J Clin 2013;63:11-30
   PubMed Web of Science ®Google Scholar
• Keedy VL, Temin S, Somerfield MR. American society of clinical oncology provisional clinical opinion: epidermal growth factor receptor (EGFR) mutation testing for patients with advanced non-small cell lung cancer considering first-line EGFR tyrosine kinase inhibitor therapy. J Clin Oncol 2011;29:2121-7
   PubMed Web of Science ®Google Scholar
• Brandao GDA, Brega EF, Spatz A. The role of molecular pathology in non-small-cell lung carcinoma-now and in the future. Curr Oncol 2012;19:S24-32
   Google Scholar
• Masago K, Fujita S, Irisa K, et al. Good clinical response to gefitinib in a non-small cell lung cancer patient harbouring a rare somatic epidermal growth factor gene point mutation; Codon 768 AGC> ATC in exon 20 (S768I). J Clin Oncol 2010;40:1105-9
   Google Scholar
• Billah S, Stewart J, Staerkel G, et al. EGFR and KRAS mutations in lung carcinoma. Molecular testing by using cytology specimens. Cancer Cytopathol 2011;119:111-17
   PubMed Web of Science ®Google Scholar
• Da Cunha Santos G, Saieg MA, Geddie W, Leigh N. EGFR gene status in cytological samples of nonsmall cell lung carcinoma: controversies and opportunities. Cancer Cytopathol 2011;119:80-91
   Google Scholar
• Smouse JH, Cibas ES, Janne PA, et al. EGFR mutations are detected comparably in cytological and surgical pathology specimens of nonsmall cell lung cancer. Cancer Cytopathol 2009;117:67-72
   Web of Science ®Google Scholar
• Malapelle U, De Rosa N, Bellevicine C, et al. EGFR mutations detection on liquid based cytology: is microscopy still necessary? J Clin Pathol 2012;65:940-4
   PubMed Web of Science ®Google Scholar
• Malapelle U, De Rosa N, Rocco D, et al. EGFR and KRAS mutations detection on lung liquid based cytology: a pilot study. J Clin Pathol 2012;65:87-91
   Google Scholar
• Rossi ED, Gerhard R, Cirnes L, et al. Detection of common and less frequent EGFR mutations in cytological samples of lung cancers. Acta Cytol 2014;58:275-80
   Google Scholar
• Marchetti A, Del Grammastro M, Filice G, et al. Complex mutations and subpopulations of deletions at exon 19 of EGFR in NSCLC revealed by next generation sequencing: potential clinical implications. PLoS One 2012;7:e42164
   Google Scholar
• Buttita F, Felicioni L, Del Grammastro M, et al. Effective assessmnet of egfr muation status in bronchoalveolar lavage and pleural fluids by next generation sequencing. Clin Can Res 2013;19:691-8
   Google Scholar
• Porcel JM, Gasol A, Bielsa S, et al. Clinical features and survival of lung cancer patients with pleural effusions. Respirology 2015;10.1111/resp.12496. [Epub ahead of print]
   Google Scholar
• Lee YM, Hwang JY, Son SM, et al. Comparison of diagnostic accuracy between cellprepPlus and ThinPrep liquid-based preparations in effusion cytology. Diagn Cytopathol 2014;42:384-90
   Google Scholar
• Gong Y, Sun X, Michael CW, et al. Immunocytochemistry of serous effusion specimens: A comparison of ThinPrep vs cell block. Diagn Cytopathol 2003;28:1-5
   PubMed Web of Science ®Google Scholar
• Hoda RS. Non-gynecologic cytology on liquid based cytology preparations: A morphologic review of facts and artifacts. Diagn Cytopathol 2007;35:621-34
   Google Scholar
• Giarnieri E, Bellipanni G, Macaluso M, et al. Cell dynamics in malignant pleural effusions. J Cell Physiol 2014;10.1002/jcp.24806
   Google Scholar
• Liao ND, Shieh JM, Lee WY. Diagnostic value of metabolic phenotypes in malignant pleural effusions: expression of GLUT1 and CAIX by immunocytochemistry. Cancer Cytopathol 2011;119(5):346-53
   PubMed Web of Science ®Google Scholar
• Hyun TS, Barnes M, Tabatabai ZL. The diagnostic utility of D2-40, calretinin, CK5/6, desmin and MOC-31 in the differentiation of mesothelioma from adenocarcinoma in pleural effusion cytology. Acta Cytol 2012;56(5):527-32
   Google Scholar
• Shabaik A, Lin G, Peterson M, et al. Reliability of Her2/neu, estrogen receptor, and progesterone receptor testing by immunohistochemistry on cell block of FNA and serous effusions from patients with primary and metastatic breast carcinoma. Diagn Cytopathol 2011;39(5):328-32
   Google Scholar
• Longatto Filho A, de Carvalho LV, Santos G, et al. Cytologic diagnosis of melanoma in serous effusions. A morphologic and immunocytochemical study. Acta Cytol 1995;39(3):481-4
   Google Scholar
• Ylagan LR, Zhai J. The value of ThinPrep and cytospin preparation in pleural effusion cytological diagnosis of mesothelioma and adenocarcinoma. Diagn Cytopathol 2005;32:137-44
   Google Scholar
• Rossi ED, Bizzarro T, Schmitt F, Longatto-Filho A. The role of liquid based cytology and ancillary techniques in the pleural and pericardic effusions: Our institutional experience. Cancer Cytopathol 2015; Epub ahead of print
   Google Scholar
• Shah RH, Scott SN, Brannon AR, et al. Comprehensive mutation profiling by next-generation sequencing of effusion fluids from patients with high-grade serous ovarian carcinoma. Cancer Cytopathol 2015; Epub ahead of print
   Google Scholar
• Davidson B, Smith Y, Nesland JM, et al. Defining a prognostic marker panel for patients with ovarian serous carcinoma effusion. Hum Pathol 2013;44(11):2449-60
   Google Scholar
• Elstrand MB, Stavnes HT, Tropé CG, Davidson B. Heat shock protein 90 is a putative therapeutic target in patients with recurrent advanced-stage ovarian carcinoma with serous effusions. Hum Pathol 2012;43(4):529-35
   Google Scholar
• Hjerpe E, Brage SE, Frostvik Stolt M, et al. Metabolic markers and HSP60 in chemonaive serous solid ovarian cancer versus ascites. Int J Gynecol Cancer 2014;24:1389-94
   Google Scholar
• Hernlund E, Hjerpe E, Avall-Lundqvist E, Shoshan M. Ovarian carcinoma cells with low levels of beta-F1-ATPase are sensitive to combined platinum and 2-deoxy-D-gucose treatment. Mol Cancer Ther 2009;8:1916-23
   PubMedGoogle Scholar
• McIntyre A, Harris AL. Metabolic and hypoxic adaptation to anti-angiogenic therapy: a target for induced essentiality. EMBO Mol Med 2015;pii:e201404271-10.15252/emmm.201404271; Epub ahead of print
   Google Scholar
• Yano S, Li Q, Wang W, et al. Antiangiogenic therapies for malignant pleural mesothelioma. Front Biosci 2011;16:740-8
   PubMed Web of Science ®Google Scholar
• Liao ND, Shieh JM, Lee WY. Diagnostic value of metabolic phenotypes in malignant pleural effusions: expression of GLUT1 and CAIX by immunocytochemistry. Cancer Cytopathol 2011;119(5):346-53
   PubMed Web of Science ®Google Scholar
• Burstein DE, Reder I, Weiser K, et al. GLUT1 glucose transporter: a highly sensitive marker of malignancy in body cavity effusions. Mod Pathol 1998;11(4):392-6
   Google Scholar
• Fang SC, Zhang HT, Hu HD, et al. Effect of Endostar combined with angiopoietin-2 inhibitor on malignant pleural effusion in mice. Med Oncol 2015;32(1):410
   Google Scholar
• Nassar A. Core needle biopsy versus fine needle aspiration biopsy in breast – a historical perspective and opportunities in modern era. Diagn Cytopathol 2011;39:380-8
   Google Scholar
• Kocjan G, Bourgain C, Fassina A, et al. The role of breast FNAC in diagnosis and clinical management: a survey of current practice. Cytopathology 2008;19:271-8
   PubMedGoogle Scholar
• Rosa M, Mohammadi A, Masood S. The value of fine needle aspiration biopsy in the diagnosis and prognostic assessment of palpable breast lesions. Diagn Cytopathol 2012;40:26-34
   Google Scholar
• Feoli F, Ameye L, Van Eeckhout P, et al. Liquid-based cytology of the breast: pitfalls unrecognized before specific liquid-based cytology training - proposal for a modification of the diagnostic criteria. Acta Cytol 2013;57:369-76
   Google Scholar
• Ryu HS, Park IA, Park SY, et al. A pilot study evaluating liquid-based fine needle aspiration cytology of breast lesions: a cytomorphological comparison of SurePath® liquid-based preparations and conventional smears. Acta Cytol 2013;57:391-9
   Google Scholar
• Veneti S, Daskalopoulou D, Zervoudis S, et al. Liquid-based cytology in breast fine needle aspiration. Comparison with the conventional smear. Acta Cytol 2003;47:188-92
   Google Scholar
• Komatsu K, Nakanishi Y, Seki T, et al. Application of liquid-based preparation to fine needle aspiration cytology in breast cancer. Acta Cytol 2008;52:591-6
   Google Scholar
• Allred C, Miller K, Viale G. Molecular testing for estrogen receptor, progesterone receptor, and HER. In: Lakhani SR, Ellis IO, Schnitt SJ, Tan PH, van de Vijver MJ, editors. who classification of tumors of the breast. IARC; Lyon: 2012. p. 22-3
   Google Scholar
• Cano G, Milanezi F, Leitão D, et al. Estimation of hormone receptor status in fine-needle aspirates and paraffin-embedded sections from breast cancer using the novel rabbit monoclonal antibodies SP1 and SP2. Diagn Cytopathol 2003;29:207-2011
   Google Scholar
• Leung SW, Bédard YC. Estrogen and progesterone receptor contents in ThinPrep-processed fine-needle aspirates of breast. Am J Clin Pathol 1999;112:50-6
   Google Scholar
• Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology; College of American Pathologists. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007;25:118-45
   PubMed Web of Science ®Google Scholar
• Williams SL, Birdsong GG, Cohen C, Siddiqui MT. Immunohistochemical detection of estrogen and progesterone receptor and HER2 expression in breast carcinomas: comparison of cell block and tissue block preparations. Int J Clin Exp Pathol 2009;2:476-80
   PubMedGoogle Scholar
• Shabaik A, Lin G, Peterson M, et al. Reliability of HER2/neu, estrogen receptor, and progesterone receptor testing by immunohistochemistry on cell block of FNA and serous effusions from patients with primary and metastatic breast carcinoma. Diagn Cytopathol 2011;39:328-32
   Google Scholar
• Gorman BK, Kosarac O, Chakraborty S, et al. Comparison of breast carcinoma prognostic/predictive biomarkers on cell blocks obtained by various methods: cellient, formalin and thrombin. Acta Cytol 2012;56:289-96
   Web of Science ®Google Scholar
• Vocaturo A, Novelli F, Benevolo M, et al. Chromogenic in situ hybridization to detect HER-2/neu gene amplification in histological and ThinPrep-processed breast cancer fine-needle aspirates: a sensitive and practical method in the trastuzumab era. Oncologist 2006;11:878-86
   PubMed Web of Science ®Google Scholar
• Beraki E, Sauer T. Determination of HER-2 status on FNAC material from breast carcinomas using in situ hybridization with dual chromogen visualization with silver enhancement (dual SISH). Cytojournal 2010;7:21
   PubMedGoogle Scholar